Legal Representation
Attorney
Christian Wolff
USPTO Deadlines
Next Deadline
988 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-03-22)
Due Date
March 22, 2028
Grace Period Ends
September 22, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
35 events| Date | Code | Type | Description |
|---|---|---|---|
| Sep 5, 2022 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Aug 16, 2022 | FIMP | P | FINAL DISPOSITION PROCESSED |
| Aug 16, 2022 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB |
| Jun 22, 2022 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Mar 22, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Mar 21, 2022 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Mar 2, 2022 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Mar 2, 2022 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Jan 22, 2022 | GPNX | P | NOTIFICATION PROCESSED BY IB |
| Jan 4, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jan 4, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Dec 15, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Dec 15, 2021 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Dec 15, 2021 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Nov 27, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Nov 26, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Nov 25, 2021 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Nov 25, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jun 1, 2021 | ALIE | A | ASSIGNED TO LIE |
| Jun 1, 2021 | CNFR | R | FINAL REFUSAL WRITTEN |
| Jun 1, 2021 | GNFR | O | FINAL REFUSAL E-MAILED |
| Jun 1, 2021 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Jun 1, 2021 | DMCC | I | DATA MODIFICATION COMPLETED |
| May 6, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| May 6, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| May 6, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Dec 13, 2020 | RFNT | P | REFUSAL PROCESSED BY IB |
| Nov 25, 2020 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Nov 24, 2020 | RFRR | P | REFUSAL PROCESSED BY MPU |
| Nov 8, 2020 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Nov 7, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Nov 6, 2020 | DOCK | D | ASSIGNED TO EXAMINER |
| Oct 3, 2020 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Sep 29, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Sep 24, 2020 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 005
Pharmaceutical and veterinary products, namely, pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders, pharmaceutical products for the prevention and treatment of cancer, pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines, and chemical reagents for medical or veterinary purposes; sanitary preparations for medical use; dietetic foodstuffs and preparations for medical or veterinary purposes, namely, dietetic foods and beverages adapted for medical use, dietetic foods adapted for veterinary use, dietetic beverages adapted for veterinary use, and dietetic preparations adapted for medical purposes; dietary supplements for humans and animals; pharmaceutical products in the nature of oils, powders and capsules containing omega-3-extracts for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; nutritional supplements; dietetic preparations adapted for medical purposes containing omega-3-extracts and in the form of oils, powders and capsules containing omega-3-extracts
First Use Anywhere:
0
First Use in Commerce:
0
Class 040
Contract manufacturing for others of pharmaceutical products, dietary supplements and dietetic products for medical purposes containing omega-3-extracts in the form of oils, powders and capsules
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Scientific and technological services, namely, pharmaceutical research and development, pharmaceutical products development, testing of pharmaceuticals, development of pharmaceutical preparations and medicines, scientific research in the field of pharmaceuticals, pharmaceutical research services, laboratory research services relating to pharmaceuticals, scientific analysis in the field of nutritional supplements; scientific research and development in the field of lipid extraction from natural resources; scientific laboratory services; chemical laboratories; scientific and industrial research for others relating to the manufacture of pharmaceutical products, dietary supplements and dietetic products for medical purposes containing omega-3-extracts in the form of oils, powders and capsules
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
040
042